MRK

Merck & Co
D

MRK

Arincen67/100B

Merck & Co net income 1985–2026

Merck & Co earned 5.07B USD in Q3 FY2026, the three months to 30 September 2026, down 12.4% on the same quarter a year before. Merck & Co's net income over the last twelve months was 2.45B USD, down 87.1% on the twelve months before. In fiscal year 2025 it earned 18.25B USD, up 6.6% on the year before.

Last updated 7 Nov 2026 · Next report 2 Feb 2027

Net income

Net income · +15.2% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 20262.45B-87.11%3.64%67.30B
FY202531 Dec 202518.25B+6.64%28.12%64.93B
FY202431 Dec 202417.12B+4,589.59%26.68%64.17B
FY202331 Dec 2023365.00M-97.49%0.61%60.12B
FY202231 Dec 202214.52B+11.27%24.49%59.28B
FY202131 Dec 202113.05B+84.65%26.79%48.70B
FY202031 Dec 20207.07B-28.20%17.02%41.52B
FY201931 Dec 20199.84B+58.25%25.16%39.12B
FY201831 Dec 20186.22B+159.82%14.71%42.29B
FY201731 Dec 20172.39B-38.93%5.97%40.12B
FY201631 Dec 20163.92B-11.75%9.85%39.81B
FY201531 Dec 20154.44B-62.73%11.25%39.50B
FY201431 Dec 201411.92B+170.66%28.22%42.24B
FY201331 Dec 20134.40B-28.60%10.00%44.03B
FY201231 Dec 20126.17B-1.66%13.05%47.27B
FY201131 Dec 20116.27B+628.46%13.05%48.05B
FY201031 Dec 2010861.00M-93.33%1.87%45.99B
FY200931 Dec 200912.90B+65.20%47.03%27.43B
FY200831 Dec 20087.81B+138.38%32.74%23.85B
FY200731 Dec 20073.28B-26.13%13.54%24.20B
FY200631 Dec 20064.43B-4.26%19.59%22.64B
FY200531 Dec 20054.63B-20.56%21.04%22.01B
FY200431 Dec 20045.83B-14.65%25.38%22.97B
FY200331 Dec 20036.83B-4.46%30.38%22.49B
FY200231 Dec 20027.15B-1.82%33.34%21.45B
FY200131 Dec 20017.28B+6.74%34.35%21.20B
FY200031 Dec 20006.82B+15.81%16.90%40.36B
FY199931 Dec 19995.89B+12.24%18.01%32.71B
FY199831 Dec 19985.25B+13.74%19.51%26.90B
FY199731 Dec 19974.61B+18.88%19.52%23.64B
FY199631 Dec 19963.88B+16.37%19.57%19.83B
FY199531 Dec 19953.34B+11.28%19.99%16.68B
FY199431 Dec 19943.00B+38.35%20.02%14.97B
FY199331 Dec 19932.17B+9.17%20.63%10.50B
FY199231 Dec 19921.98B-6.48%20.54%9.66B
FY199131 Dec 19912.12B+19.12%24.66%8.60B
FY199031 Dec 19901.78B+19.11%23.22%7.67B
FY198931 Dec 19891.50B+23.91%22.83%6.55B
FY198831 Dec 19881.21B+33.14%20.32%5.94B
FY198731 Dec 1987906.40M+34.14%17.91%5.06B
FY198631 Dec 1986675.70M+25.15%16.37%4.13B
FY198531 Dec 1985539.90M—15.22%3.55B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Merck & Co's profit

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.